Get the Stockscreener App
266.11
0.61%
1.61
Alnylam Pharmaceuticals Inc stock is traded at $266.11, with a volume of 1.42M.
It is up +0.61% in the last 24 hours and up +21.51% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
See More
Previous Close:
$264.50
Open:
$258.58
24h Volume:
1.42M
Relative Volume:
0.81
Market Cap:
$35.61B
Revenue:
$4.29B
Net Income/Loss:
$577.22M
P/E Ratio:
63.23
EPS:
4.2086
Net Cash Flow:
$641.34M
1W Performance:
+12.24%
1M Performance:
+21.51%
6M Performance:
-18.70%
1Y Performance:
-41.33%
1-Day Range:
$258.02
$266.85
1-Week Range:
$233.33
$271.19
52-Week Range:
$197.81
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
266.11 | 30.68B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-07-26 | Resumed | Oppenheimer | Outperform |
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Alnylam Pharmaceuticals (ALNY) Could Be 39% Undervalued On Fresh ESC 2026 Data - simplywall.st
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech - ChartMill
ALNY Stock Climbs As Analysts Turn Bullish After ESC Data - StocksToTrade
ALNY Stock Rebounds As Analysts Back RNAi Momentum - timothysykes.com
ALNY Stock Rebounds As Analysts Back RNAi Growth Story - timothysykes.com
Alnylam Pharmaceuticals Inc Stock (ALNY) Moved Up by 7.90% on Sep 2: Facts Behind the Movement - TradingKey
Alnylam Pharmaceuticals gains as investors digest fresh ESC data and upcoming conference appearances - Quiver Quantitative
Alnylam to Webcast Presentations at Upcoming September Investor Conferences - Business Wire
ALNY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $455 - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY) - The Globe and Mail
Expanded RNAi Cardio Data Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY) - simplywall.st
Alnylam Pharmaceuticals (ALNY) Investor Outlook: Exploring a 56% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Alnylam data support Amvuttra across ATTR patient groups, advance hypertension drug case (ALNY:NASDAQ) - Seeking Alpha
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings - Yahoo Finance
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Alnylam drops as AstraZeneca posts full trial results for failed heart drug - Seeking Alpha
Why Everyone Is Watching Alnylam Pharmaceuticals (ALNY) Today - simplywall.st
ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc. - GlobeNewswire
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026 - Business Wire
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with 56.72% Potential Upside - DirectorsTalk Interviews
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week - AOL.com
Silvant Capital Management LLC Takes $5.46 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Wealthfront Advisers LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
NewEdge Wealth LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Biotech Is Booming, But These 2 Stocks Missed the Memo - Sahm
Danske Bank A S Takes $19.43 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Lowered TTR Sales Outlook And Legal Probe Might Change The Case For Investing In Alnylam (ALNY) - simplywall.st
Bragar Eagel & Squire, P.C. is Investigating Alnylam - GlobeNewswire
Securities Fraud Investigation Into Alnylam - GlobeNewswire
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to "Strong-Buy" at BMO Capital Markets - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention - ChartMill
Mitsubishi UFJ Asset Management Co. Ltd. Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
NewEdge Advisors LLC Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
E Fund Management Co. Ltd. Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
(NASDAQ: ALNY): Investigation Launched Into Alnylam Pharmaceuticals, Inc. by Kessler Topaz Meltzer & Check, LLP - Barchart.com
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - WBOC TV
NASDAQ: ALNY: Kessler Topaz Meltzer & Check, LLP Launches Investigation Into Alnylam Pharmaceuticals, Inc. - NewMediaWire
Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today - Quiver Quantitative
Alnylam initiated an outperform at BMO on RNAi pipeline - Seeking Alpha
BMO Capital Markets Initiates Coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For We - Benzinga
BMO initiates Alnylam stock with outperform on ATTR franchise growth By Investing.com - Investing.com Canada
ALNY Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing - AOL.com
ALNY ALERT: Investigation Launched Into Alnylam Pharmaceuticals, Inc., Investors Are Encouraged to Contact KTMC Law Firm - NewMediaWire
ALNY Looks 56.8% Undervalued on GF Value™ - GuruFocus
Familial Amyloid Polyneuropathy Market - Future Market Insights
ALNY Looks 56.7% Undervalued on GF Value™ - GuruFocus
Alnylam Pharmaceuticals (ALNY): Investor Outlook With A 62.82% Potential Upside - DirectorsTalk Interviews
ALNY Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm - The Globe and Mail
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Sale |
299.18 |
3,830 |
1,145,853 |
1,582 |
1.22%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):